Takayuki Yoshino, M.D.

Takayuki Yoshino, M.D.<br>Japan

“I am a leading Japanese specialist in the colorectal cancer field, particularly for clinical development of new agents as well as the translational research for investigating predictive & prognostic biomarkers and contributing to international programs. Arfolitixorin is a novel & promising compound with potential to increase the efficacy of the standard-of-care regimen without adding toxicity”.


Takayuki Yoshino M.D., is the Director for the Department of Gastroenterology and Gastrointestinal Oncology at the National Cancer Center Hospital East in Chiba, Japan, and Head of the Clinical Research Coordinating Division. Dr. Yoshino has a particular interest in chemotherapy for gastrointestinal cancers, especially for colorectal cancer, where he focuses on also on translational research regarding potential predictive and prognostic biomarkers. He has worked closely in the USA with several world-renowned institutions, including the Mayo Clinic, Dana-Farber Cancer Institute and the Vanderbilt-Ingram Cancer Center. Dr. Yoshino has had over 20 first or corresponding author publications on metastatic colorectal cancer including Lancet Oncology and The New England Journal of Medicine. Dr.Yoshino holds several professional appointments, serving on guideline member of the Japanese Society for Cancer of the Colon and Rectum, international guideline member of the European Society for Medical Oncology, and guideline member of the Japanese Society of Medical Oncology as well the administrative board for The Japanese Association for Molecular Target Therapy of Cancer.


Back to International external experts